Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PetVivo Holdings ( (PETV) ) has provided an announcement.
On February 14, 2025, PetVivo Holdings, Inc. entered into an Exclusive License and Supply Agreement with VetStem, Inc. to commercialize VetStem’s PrecisePRP® equine and canine products. This agreement allows PetVivo to sell and import these allogeneic orthobiologic products, which are innovative off-the-shelf platelet-rich plasma solutions for veterinary use. The agreement includes a series of milestone and royalty payments, along with an option for PetVivo to purchase certain assets from VetStem. This partnership is expected to enhance PetVivo’s market positioning in the veterinary medical devices and regenerative medicine sector by leveraging VetStem’s expertise in regenerative solutions.
More about PetVivo Holdings
PetVivo Holdings, Inc. is a biomedical device company specializing in the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals. The company focuses on adapting human therapies for veterinary use, with its flagship product being Spryng™ with OsteoCushion™ Technology, an injectable for managing joint-related issues in cats, dogs, and horses.
YTD Price Performance: -1.47%
Average Trading Volume: 30,306
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $15.26M
See more data about PETV stock on TipRanks’ Stock Analysis page.
